Immunovant (IMVT) director exercises options, sells 6,000 shares under 10b5-1 plan

Rhea-AI Filing Summary

Immunovant, Inc. director Atul Pande reported an option exercise and share sale. On May 20, 2026, he exercised stock options to acquire 6,000 shares of common stock at $8.43 per share and sold 6,000 shares at $32.00 per share.

After these transactions, he directly holds 116,731 common shares and indirectly holds 20,000 shares through a trust. A related footnote states the sale occurred under a pre-arranged Rule 10b5-1 trading plan, indicating the timing was planned in advance.

Insider Trade Summary 10b5-1

Net Seller: 6,000 shares ($192,000)

Net Sell 4 txns

Insider Pande Atul

Role null

Sold 6,000 shs ($192K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	6,000	$0.00	--
Exercise	Common Stock	6,000	$8.43	$51K
Sale	Common Stock	6,000	$32.00	$192K
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 270,252 shares (Direct, null); Common Stock — 122,731 shares (Direct, null); Common Stock — 20,000 shares (Indirect, By Trust)

Footnotes (1)

1. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025. Reflects an award of stock options to purchase Common Shares that is fully vested.

Key Figures

Shares sold: 6,000 shares Sale price: $32.00/share Exercise price: $8.43/share +5 more

8 metrics

Shares sold 6,000 shares Open-market sale of common stock on May 20, 2026

Sale price $32.00/share Price for 6,000 common shares sold

Exercise price $8.43/share Stock option exercise price for 6,000 shares

Shares acquired via exercise 6,000 shares Common stock from option exercise on May 20, 2026

Direct holdings after transactions 116,731 shares Common stock directly owned following transactions

Indirect holdings via trust 20,000 shares Common stock held indirectly by trust

Remaining stock options 270,252 options Stock options following derivative transaction

Net share change -6,000 shares Net buy/sell shares from reported transactions

Key Terms

Rule 10b5-1 Plan, Stock Option (right to buy), open-market sale, indirect ownership, +1 more

5 terms

Rule 10b5-1 Plan financial

"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

Stock Option (right to buy) financial

"Stock Option (right to buy) with 6,000 underlying shares of Common Stock at an $8.43 exercise price."

open-market sale financial

"Sale in open market or private transaction for 6,000 shares of Common Stock at $32.00 per share."

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

indirect ownership financial

"Common Stock held with ownership type marked as indirect and nature of ownership "By Trust" for 20,000 shares."

derivative exercise/conversion financial

"Transaction code M described as derivative exercise/conversion for stock options into Common Stock."

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pande Atul

(Last) (First) (Middle)

C/O IMMUNOVANT, INC.

1000 PARK FORTY PLAZA, SUITE 210

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immunovant, Inc. [ IMVT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/20/2026		M(1)		6,000	A	$8.43	122,731	D
Common Stock	05/20/2026		S(1)		6,000	D	$32	116,731	D
Common Stock								20,000	I	By Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$8.43	05/20/2026		M(1)			6,000	(2)	11/19/2029	Common Stock	6,000	$0	270,252	D

Explanation of Responses:

1. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025.

2. Reflects an award of stock options to purchase Common Shares that is fully vested.

Remarks:

	/s/ Tiago Girao, attorney-in-fact for Atul Pande	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Immunovant (IMVT) director Atul Pande report?

Director Atul Pande exercised stock options for 6,000 Immunovant shares at $8.43 and sold 6,000 shares at $32.00 on May 20, 2026. The filing shows an exercise-and-sell pattern combined with remaining direct and indirect share ownership.

At what prices did Atul Pande exercise and sell Immunovant (IMVT) shares?

He exercised options to acquire 6,000 Immunovant shares at $8.43 per share, then sold 6,000 shares at $32.00 per share. This reflects an option exercise followed by an open-market sale at a substantially higher market price.

How many Immunovant (IMVT) shares does Atul Pande hold after the reported transactions?

After the transactions, Atul Pande directly holds 116,731 Immunovant common shares and indirectly holds 20,000 shares through a trust. The filing also reports 270,252 stock options remaining, providing additional potential future equity exposure.

Were Atul Pande’s Immunovant (IMVT) share sales under a Rule 10b5-1 plan?

Yes. A footnote states the reported transaction occurred pursuant to a Rule 10b5-1 plan adopted on December 26, 2025. Such pre-arranged plans automate trading, so the timing of the May 20, 2026 sale was scheduled in advance.

What type of derivative security did Atul Pande exercise in Immunovant (IMVT)?

He exercised a stock option, described as a "Stock Option (right to buy)", covering 6,000 underlying Immunovant common shares at a $8.43 exercise price. Following the exercise, 270,252 stock options remain reported as held directly.